AI assistant
Dechra Pharmaceuticals PLC Director's Dealing 2020
4797_dirs_2020-09-18_be1fdd5d-bc8e-4cbe-99a3-b790a263ee99.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 4651Z
Dechra Pharmaceuticals PLC
18 September 2020
18 September 2020
Dechra Pharmaceuticals PLC
Notification of Transactions by Persons Discharging Managerial Responsibilities
On 18 September 2020, Dechra Pharmaceuticals PLC was notified by a Director of the Company and Person Discharging Managerial Responsibilities that he had completed a transfer of part of his beneficial interest in Dechra.
Ian Page, Executive Director, has transferred 2,000 ordinary shares in the Company to his son, David Page. Following these transactions, Ian Page will continue to retain a beneficial holding of 623,374 ordinary shares which represents 0.577% of the current issued share capital in the Company.
The Notification of Dealing Form set out below is provided in accordance with Article 19.3 of MAR.
Notification of Dealing Form:
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director | |
| b) | Initial notification/amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Transfer of Shares | |
| c) | Price(s) and volumes(s) | Price(s) £N/A |
Volume(s) 2,000 |
| d) | Aggregated information -Aggregate volume - Price - Total |
2,000 £N/A £N/A |
|
| e) | Date of the transaction | 18 September 2020 | |
| f) | Place of the transaction | Outside a trading venue |
| Enquiries: | |
| Dechra Pharmaceuticals PLC | |
| Ian Page, Chief Executive Officer | Office: +44 (0) 1606 814 730 |
| Paul Sandland, Acting Chief Financial Officer e-mail: [email protected] |
Office: +44 (0) 1606 814 730 |
| TooleyStreet Communications Ltd | |
| Fiona Tooley, Director e-mail: [email protected] |
Office: +44 (0) 121 309 0099 Mobile: +44 (0) 7785 703 523 |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKFBDDBKDQCD